INO-VATE analysis demonstrates benefits for younger and older ALL patients
medwireNews: Further analysis of the INO-VATE study shows that inotuzumab ozogamicin (InO) is effective across the adult acute lymphoblastic leukemia (ALL) patient age range, although those aged less than 55 years may derive greater overall survival (OS) benefit.
The initial study findings showed that receipt of up to six cycles of InO 1.8 mg/m2 led to a significantly higher rate of complete remission than a physician’s choice of chemotherapy for patients with relapsed or refractory ALL undergoing a first or second line of salvage therapy
The current intent-to-treat analysis, published in Cancer, indicates that patients aged 55 years or older received InO therapy for a similar duration to younger patients and had a comparable experience in terms of adverse events.
This resulted in the two age groups experiencing a similar remission rate, duration of remission, and progression-free survival, write Elias Jabbour, from the University of Texas MD Anderson Cancer Center in Houston, USA, and co-workers.
However, younger patients achieved significantly longer OS with InO than chemotherapy (median 8.6 vs 8.0 months, hazard ratio [HR]=0.68), whereas the OS benefit of InO was not significant for older adults. And among InO-treated patients, younger adults had significantly longer median OS than older patients (8.6 vs 5.6 months, HR=0.61).
This difference in OS could be attributed to the greater proportion of younger patients who subsequently underwent hematopoietic stem cell transplantation, the researchers postulate.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group